mardi 28 mars 2017

Onco Actu du 28 mars 2017

1. Biologie

How Randomness Helps Cancer Cells Thrive [Johns Hopkins]

A leading science institute finds beauty in the most microscopic of places [STAT]

2.5 Etiologie - Gènes

Largest-ever brain cancer study reveals new secrets to inherited risk [The Institute of Cancer Research]

3.5 Prévention - UV

Mothers often take daughters to first tanning salon visit [Reuters]

4. Dépistage, diagnostic et pronostic

Detecting mutations could lead to earlier liver cancer diagnosis [MIT News]

4.1 Dép., diag. & prono. - Prostate

MRI use may “change the equation” for prostate cancer screening [EAU]

Scientists report genetic test to help predict men at most risk from aggressive prostate cancer [EAU]

4.2 Dép., diag. & prono. - Génome

An Evidence Framework for Genetic Testing [National Academies Press]

5. Traitements

Targeted Cancer Drug May Also Help Protect Fertility, Study Suggests [NCI]

Targets: Drugability Revisited [Omics! Omics!]

5.12 Immunothérapies

Study provides path for new immunotherapy approaches to prostate cancer [MD Anderson]

5.12.1 Immunothérapies - partenariats

Swiss antibody shop Numab strikes an immuno-oncology discovery deal with Japan’s Ono [EndPoints]

5.2 Pharma

TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer [Tesaro]

Liver cancer miss adds to litany of trial failures for ArQule's tivantinib [FierceBiotech]

MELK Is Not A Cancer Target. Surprise! [In the Pipeline]

Erytech Reports Positive Phase 2B Data for Eryaspase for the Treatment of Metastatic Pancreactic Cancer [Erytech]

5.3.4 Traitements - AMM (FDA, EMA)

Tesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparib [FiercePharma]

Tesaro Announces U.S. FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer [Tesaro]

Tesaro’s Ovarian Cancer Drug Gets FDA Nod, No Diagnostic Needed [Xconomy]

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer [The Street]

FDA OKs Tesaro’s niraparib for ovarian cancer, handing the biotech a big win on the label [EndPoints]

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers [FDA]

5.4 Traitements - Economie

New budget test puts UK on front line in global drug price fight [Reuters]

6.10.1 Politiques (USA)

Playing no Trump at AAAS policy forum [Science]

6.12 Ethique

‘I’m Willing To Try Anything’: Compassionate Use Access To Experimental Drugs And The Misguided Mission Of Right-To-Try Laws [Health Affairs Blog]

6.6 Publications

Challenges of Measuring Persistent Identifier (PID) Adoption [ORCID]

How Elsevier plans to sabotage Open Access [Medium]

6.9 Controverses

Soon-Shiong’s promotion of ‘breakthrough’ cancer therapy raises questions [STAT]